Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday

Theravance Biopharma (NASDAQ:TBPHGet Free Report) is set to issue its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Theravance Biopharma (NASDAQ:TBPHGet Free Report) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The company had revenue of $14.26 million for the quarter, compared to the consensus estimate of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same quarter in the previous year, the company posted ($0.28) EPS. On average, analysts expect Theravance Biopharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Theravance Biopharma Stock Up 0.7 %

TBPH traded up $0.06 during trading on Tuesday, hitting $8.27. 2,863 shares of the company traded hands, compared to its average volume of 348,869. The firm has a market cap of $404.57 million, a P/E ratio of -8.92 and a beta of 0.25. The stock’s fifty day moving average is $8.26 and its 200 day moving average is $8.70. Theravance Biopharma has a one year low of $7.44 and a one year high of $11.71.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. Finally, TD Cowen reduced their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $13.75.

Get Our Latest Report on TBPH

Insider Transactions at Theravance Biopharma

In other news, major shareholder Eli Samaha bought 999,800 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were purchased at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the acquisition, the insider now owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 6.90% of the company’s stock.

About Theravance Biopharma

(Get Free Report)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Read More

Earnings History for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.